ENVASARC: ENVAFOLIMAB AND ENVAFOLIMAB WITH IPILIMUMAB IN PATIENTS WITH UNDIFFERENTIATED PLEOMORPHIC SARCOMA OR MYXOFIBROSARCOMA (ENVASARC)
This is a multicenter open-label, randomized, non-comparative, parallel cohort pivotal study of treatment with envafolimab (cohort A and C) or envafolimab combined with ipilimumab (cohort B and D) in patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS)/myxofibrosarcoma (MFS) who have progressed on one or two lines of chemotherapy.
ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT04480502?term=envafolimab&draw=4
Sponsor website: www.traconpharma.com